Plain-language summary

This Phase 2 trial is testing Ruxolitinib and Pembrolizumab for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join (key eligibility)

• Age 18 Years to 95 Years years
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Ruxolitinib (DRUG): Patients will receive the study drug ruxolitinib for as long as the disease responds, for up to a maximum of one year (or 17 cycles). After study treatment with ruxolitinib is finished, the study doctor will continue to watch for side effects and follow the condition for one year. If any side effects are experienced, the study doctor will follow up until resolution or stabilization of the side effect. | Pembrolizumab (DRUG): Pembrolizumab immunotherapy will be administered intravenously at 200 mg once every 21 days. Subjects will receive pembrolizumab for as long as the disease responds, up to a maximum of one year (or 17 cycles). Each cycle is 21 days long.

Drugs / treatments

Ruxolitinib, Pembrolizumab

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details